Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion to Expand Blood Cancer Pipeline

Lilly’s acquisition targets disease-modifying therapies for essential thrombocythemia and myelofibrosis.

Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion to Expand Blood Cancer Pipeline
Credit: PRNewswire/Calytrix Bio
Already have an account? Sign in.